HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lili Chen Selected Research

Metaphyseal Anadysplasia 1

11/2019A de novo variant in MMP13 identified in a patient with dominant metaphyseal anadysplasia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lili Chen Research Topics

Disease

94Neoplasms (Cancer)
12/2022 - 10/2004
32Inflammation (Inflammations)
07/2022 - 09/2004
30Infections
12/2022 - 02/2005
21Neoplasm Metastasis (Metastasis)
07/2022 - 01/2012
14Carcinogenesis
01/2022 - 08/2015
12Breast Neoplasms (Breast Cancer)
08/2022 - 03/2009
11Prostatic Neoplasms (Prostate Cancer)
08/2021 - 01/2004
10Wounds and Injuries (Trauma)
01/2022 - 03/2013
10Type 2 Diabetes Mellitus (MODY)
01/2018 - 01/2011
9Periodontitis
01/2022 - 01/2014
9Atherosclerosis
01/2021 - 12/2009
8Insulin Resistance
06/2021 - 01/2011
8Lung Neoplasms (Lung Cancer)
01/2021 - 09/2010
8Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2019 - 06/2010
7Hepatocellular Carcinoma (Hepatoma)
12/2022 - 08/2012
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 03/2012
6Carcinoma (Carcinomatosis)
01/2019 - 09/2009
6Malaria
12/2011 - 07/2008
5Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 06/2013
5Pain (Aches)
01/2022 - 02/2003
5Body Weight (Weight, Body)
01/2020 - 09/2011
4Necrosis
10/2021 - 01/2017
4Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 01/2016
4Osteoporosis
01/2021 - 01/2016
4COVID-19
01/2021 - 07/2020
4Bone Resorption
01/2021 - 05/2012
4Adenocarcinoma of Lung
05/2019 - 01/2019
4Multiple Myeloma
04/2016 - 07/2014
3Triple Negative Breast Neoplasms
01/2022 - 01/2021
3Papillary Thyroid Cancer
01/2022 - 01/2019
3Colitis
01/2022 - 10/2018
3Alveolar Bone Loss
01/2021 - 06/2019
3Melanoma (Melanoma, Malignant)
01/2021 - 01/2021
3Nasopharyngeal Carcinoma
01/2021 - 01/2014
3Stomach Neoplasms (Stomach Cancer)
01/2021 - 10/2011
3Squamous Cell Carcinoma of Head and Neck
01/2021 - 09/2010
3Brain Ischemia (Cerebral Ischemia)
01/2021 - 01/2016
3Reperfusion Injury
03/2020 - 10/2017
3Myocardial Infarction
01/2020 - 01/2004

Drug/Important Bio-Agent (IBA)

29Proteins (Proteins, Gene)FDA Link
02/2022 - 02/2005
22Pharmaceutical PreparationsIBA
12/2022 - 02/2005
19Biomarkers (Surrogate Marker)IBA
08/2022 - 01/2004
16Glucose (Dextrose)FDA LinkGeneric
06/2021 - 01/2011
15CytokinesIBA
01/2021 - 09/2004
12Messenger RNA (mRNA)IBA
01/2022 - 02/2014
11Long Noncoding RNAIBA
12/2022 - 01/2016
10MicroRNAs (MicroRNA)IBA
01/2022 - 09/2014
9RNA (Ribonucleic Acid)IBA
10/2022 - 01/2016
9Biological ProductsIBA
01/2022 - 10/2013
9EnzymesIBA
10/2021 - 10/2009
7Doxorubicin (Adriamycin)FDA LinkGeneric
10/2021 - 02/2005
7LigandsIBA
12/2020 - 12/2011
7Small Interfering RNA (siRNA)IBA
06/2019 - 10/2011
6Anti-Bacterial Agents (Antibiotics)IBA
10/2022 - 11/2006
6AntigensIBA
02/2022 - 05/2009
6Therapeutic UsesIBA
01/2022 - 10/2008
6LipidsIBA
10/2021 - 12/2013
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2021 - 09/2010
6CollagenIBA
01/2019 - 03/2015
5Interleukin-23 (Interleukin 23)IBA
01/2022 - 10/2018
5Interleukin-17 (Interleukin 17)IBA
07/2021 - 12/2009
5NADPH Oxidases (NAD(P)H oxidase)IBA
01/2021 - 06/2015
5Reactive Oxygen Species (Oxygen Radicals)IBA
10/2017 - 01/2012
4C-Reactive ProteinIBA
02/2022 - 01/2019
4Interleukin-6 (Interleukin 6)IBA
02/2022 - 11/2017
4Estrogens (Estrogen)FDA Link
01/2022 - 05/2012
4Insulin (Novolin)FDA Link
01/2021 - 10/2010
4Peptides (Polypeptides)IBA
01/2021 - 02/2003
4Peptide Hydrolases (Proteases)FDA Link
01/2021 - 06/2005
4Indicators and Reagents (Reagents)IBA
07/2020 - 09/2015
4Triglycerides (Triacylglycerol)IBA
09/2019 - 01/2011
4Blood Glucose (Blood Sugar)IBA
11/2016 - 01/2011
4InflammasomesIBA
04/2016 - 07/2014
3Progesterone Receptors (Progesterone Receptor)IBA
08/2022 - 05/2012
3CarbohydratesIBA
02/2022 - 10/2019
3Uric Acid (Urate)IBA
01/2022 - 08/2011
3InterleukinsIBA
01/2022 - 01/2017
3Hyaluronic Acid (Hyaluronan)IBA
10/2021 - 05/2015
3Bortezomib (Velcade)FDA Link
06/2021 - 01/2019
3Proteasome InhibitorsIBA
06/2021 - 01/2019
3CateninsIBA
04/2021 - 01/2019
3Caspase 3 (Caspase-3)IBA
01/2021 - 01/2017
3Apolipoproteins E (ApoE)IBA
01/2021 - 01/2017
3MelatoninIBA
01/2021 - 01/2020
3ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2019
3Phosphotransferases (Kinase)IBA
01/2021 - 10/2014
3Transcription Factors (Transcription Factor)IBA
01/2021 - 01/2014
3Cadherins (E-Cadherin)IBA
01/2021 - 05/2015
3AntibodiesIBA
01/2021 - 05/2009
3Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2021 - 04/2015
3CarcinogensIBA
01/2021 - 08/2015
3Glycoproteins (Glycoprotein)IBA
12/2020 - 02/2005
3Retinaldehyde (Retinal)IBA
11/2020 - 12/2018
3CholesterolIBA
10/2020 - 08/2012
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2020 - 12/2014

Therapy/Procedure

40Therapeutics
12/2022 - 02/2010
15Radiotherapy
08/2021 - 01/2004
14Drug Therapy (Chemotherapy)
12/2022 - 05/2010
5Immunotherapy
01/2021 - 01/2021
4Aftercare (After-Treatment)
01/2022 - 05/2014